HB0056 / Zhejiang Huahai Pharma - LARVOL DELTA

...Huaotai HB0056 (TSLP/IL-11 Bispecific Antibody) Completes Enrollment and Dosing of First Patient for Asthma Indication [Google translation] (Sina Corp)

Trial status • Asthma

Clinical trial of new asthma drug: TSLP/IL-11 nano dual-antibody new drug HB0056 injection [Google translation] (Sohu.com) - "HB0056 is a bispecific antibody with anti-TSLP humanized monoclonal antibody as the parent antibody and anti-IL-11 single-chain nanobody connected at the N-terminus...Study drug: HB0056 injection (Phase Ib/II); Registration number: CTR20252580; Trial type: Controlled trial (vs placebo); Indications: Asthma...Patients who have received medium-to-high-dose ICS (≥250 μg fluticasone propionate dry powder equivalent daily total dose) combined with at least one controller drug (such as LABA, LTRA, theophylline, LAMA, sodium cromolyn, etc.) for ≥3 consecutive months before screening, and maintained a stable treatment regimen and dosage for ≥1 month before screening....At least one acute asthma attack occurred within 12 months before screening."

Trial status • Asthma • Immunology • Inflammation

Huahai Pharmaceutical (600521.SH)’s subsidiary drug HB0056 injection obtained drug clinical trial approval (Investing.com) - "According to the Zhitong Finance APP, Huahai Pharmaceutical (600521.SH) announced that recently, the company's subsidiaries Shanghai Huaotai Biopharmaceutical Co., Ltd. (referred to as 'Huaotai') and Huabo Biotechnology (Shanghai) Co., Ltd. (a wholly-owned subsidiary of Huaotai, referred to as 'Huabo Bio') received the 'Drug Clinical Trial Approval Notice' for HB0056 Injection approved and issued by the State Drug Administration (referred to as 'NMPA'), and the drug is indicated for asthma."

New trial • Asthma